Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | KRAS | P01116 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21489171 | 0.92 | STING1 (0.47) | HINT1NT5EFUT5GSK3ARPS6KA3 | |
| SCHEMBL21489259 | 0.92 | IMPDH2 (0.42) | HINT1NT5EFUT5GSK3ARPS6KA3 | |
| SCHEMBL21473293 | 0.91 | HINT1 (0.51) | HINT1NT5EFUT5GSK3ARPS6KA3 | |
| SCHEMBL21489365 | 0.91 | HINT1 (0.51) | HINT1NT5EFUT5GSK3ARPS6KA3 | |
| SCHEMBL21489200 | 0.89 | HINT1 (0.51) | HINT1NT5EFUT5GSK3ARPS6KA3 | |
| SCHEMBL29479240 | 0.85 | HINT1 (0.57) | HINT1NT5EFUT5GSK3ARPS6KA3 | |
| SCHEMBL21489358 | 0.84 | STING1 (0.42) | HINT1NT5EFUT5STING1 | |
| SCHEMBL21489386 | 0.84 | POLB (0.48) | HINT1NT5EFUT5STING1PDE3B | |
| SCHEMBL21474251 | 0.83 | HINT1 (0.51) | HINT1NT5EFUT5GSK3ARPS6KA3 | |
| SCHEMBL21489169 | 0.83 | STING1 (0.51) | HINT1NT5EFUT5GSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-08-03 | — | — | US | disclosed |
| US-11613554-B2 | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-28 | — | — | US | disclosed |
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | HINT1 1295/4885NT5E 472/4885FUT5 4001/4885 |
| US-11613554-B2 | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds | PPIP5K2, INPP5B, PTMS | HINT1 1295/4885NT5E 472/4885FUT5 4001/4885 |
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | HINT1 949/4885NT5E 379/4885FUT5 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.